Results 71 to 80 of about 960 (168)
Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 2, Page 260-269, April 2026.We selected breast cancer‐specific DNA methylation markers using The Cancer Genome Atlas (TCGA). We analyzed the methylation and expression patterns of candidate genes in breast cancer cell lines, ctDNA, and tissue samples. The relationship between ctDNA methylation markers and the clinicopathological features of breast cancer patients was investigated.
Young Ju Jeong +6 more
wiley +1 more source
Cancer treatment monitoring using cell-free DNA fragmentomes
Nature CommunicationsAbstractCirculating cell-free DNA (cfDNA) assays for monitoring individuals with cancer typically rely on prior identification of tumor-specific mutations. Here, we develop a tumor-independent and mutation-independent approach (DELFI-tumor fraction, DELFI-TF) using low-coverage whole genome sequencing to determine the cfDNA tumor fraction and validate ...
Iris van ’t Erve +21 more
openaire +5 more sources
Beyond Mutation Detection: Cell-Free DNA for Functional Inference and Adaptive Oncology
DNALiquid biopsy has evolved beyond its original role as a minimally invasive approach for mutation detection and is now being developed as a broader analytical framework for cancer detection, stratification, and longitudinal monitoring.
Tetiana Zaichuk
doaj +1 more source
P125: Detection of pancreatic cancer in liquid biopsies using integrative fragmentomics
Genetics in Medicine OpenDolev Rahat +3 more
doaj +2 more sources
Advanced Science, Volume 13, Issue 13, 3 March 2026.Mature red blood cells (RBCs) can capture extracellular DNA, with short fragments homologous to cfDNA. This uptake is mediated by apoptotic bodies, which induce RBC oxidative stress, deformation, and accelerated in vivo clearance. The rbcDNA abundance correlates with tumor burden and therapeutic response, highlighting its potential as a liquid biopsy ...
Zihang Zeng +20 more
wiley +1 more source
대장암 진단 및 예후 예측를 위한 혈액내 종양DNA의 genome-wide 메틸화 및 fragmentomics 마커 발굴에 관한 연구 [PDF]
, 2022 학위논문(박사) -- 서울대학교대학원 : 융합과학기술대학원 분자의학 및 바이오제약학과, 2022.2. 김태유.Non-genetic signatures from liquid biopsy samples are emerging as feasible markers of cancer because plasma cell-free DNA (cfDNA) is representative of the patient's systemic state.
강준규
core
Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer
, 2021 Cell-free DNA (cfDNA) analysis using liquid biopsies is a non-invasive method to gain insights into the biology, therapy response, mechanisms of acquired resistance and therapy escape of various tumors. While it is well established that individual cancer
Holger Sültmann +5 more
core +1 more source
DNABackground/Objectives: Circulating cell-free DNA (cfDNA) consists of genomic DNA (cf-nDNA) and mitochondrial DNA (cf-mtDNA) fragments released from cells primarily through apoptosis and necrosis.
Patrizia Cesare +6 more
doaj +1 more source
Distinct Features of Plasma Ultrashort Single-Stranded Cell-Free DNA as Biomarkers for Lung Cancer Detection [PDF]
, 2023 BackgroundUsing broad range cell-free DNA sequencing (BRcfDNA-Seq), a nontargeted next-generation sequencing (NGS) methodology, we previously identified a novel class of approximately 50 nt ultrashort single-stranded cell-free DNA (uscfDNA) in plasma ...
Lin, Chien-Chung +16 more
core
Lymph‐based liquid biopsy: Current progress and future potential
Interdisciplinary Medicine, Volume 4, Issue 2, March 2026.Recent evidence under the revised Starling principle indicates that lymph‐based liquid biopsies may offer superior diagnostic performance over blood‐based counterparts in certain clinical scenarios, such as early‐stage solid tumor detection. Currently, various biomarkers within the lymphatic system show significant diagnostic potential for a range of ...
Dongdong Liu +6 more
wiley +1 more source